Published online Jul 26, 2021. doi: 10.4252/wjsc.v13.i7.934
Peer-review started: February 28, 2021
First decision: April 19, 2021
Revised: May 5, 2021
Accepted: July 9, 2021
Article in press: July 9, 2021
Published online: July 26, 2021
Processing time: 144 Days and 15.7 Hours
The classical cancer stem cell (CSCs) theory proposed the existence of a rare but constant subpopulation of CSCs. In this model cancer cells are organized hierarchically and are responsible for tumor resistance and tumor relapse. Thus, eliminating CSCs will eventually lead to cure of cancer. This simplistic model has been challenged by experimental data. In 2010 we proposed a novel and controversial alternative model of CSC biology (the Stemness Phenotype Model, SPM). The SPM proposed a non-hierarchical model of cancer biology in which there is no specific subpopulation of CSCs in tumors. Instead, cancer cells are highly plastic in term of stemness and CSCs and non-CSCs can interconvert into each other depending on the microenvironment. This model predicts the existence of cancer cells ranging from a pure CSC phenotype to pure non-CSC phenotype and that survival of a single cell can originate a new tumor. During the past 10 years, a plethora of experimental evidence in a variety of cancer types has shown that cancer cells are indeed extremely plastic and able to interconvert into cells with different stemness phenotype. In this review we will (1) briefly describe the cumulative evidence from our laboratory and others supporting the SPM; (2) the implications of the SPM in translational oncology; and (3) discuss potential strategies to develop more effective therapeutic regimens for cancer treatment.
Core Tip: The classical cancer stem cell theory proposed the existence of a rare but constant subpopulation of cancer stem cells. This review article briefly describes the cumulative evidence supporting alternative models of cancer stem cells, their implications in translational oncology and, discuss the potential strategies to develop more effective and less toxic sequential multistep-based therapeutic regimens for cancer treatment.